We are improving the lives of people suffering from mental illness and substance use disorders

 

What we do

US Pharma

US Pharma

HQ & Pipeline

HQ & Pipeline

Digital Therapeutics

Digital Therapeutics

At the core of a sustainable society

are health and well-being, the areas where

Orexo makes its biggest impact.

 

Key News

MAY 9, 2023
Fentanyl Awareness Day 2023: "Fentanyl is in everything and it’s killing so many people."

APRIL 27, 2023
Orexo Interim Report Q1 2023

APRIL 26, 2023
Presentation of Orexo's Q1 Interim Report 2023 - April 27 at 2 pm

amorphOX® – a versatile drug delivery platform

Orexo’s novel drug delivery platform has unique properties for the development of differentiated pharmaceuticals that need to be absorbed rapidly by the body and remain stable over time.

News Flow

Regulatory Press Releases

Financial Snapshot

Group net revenues

624  MSEK

LTM1

Group EBITDA

-159 MSEK

LTM1

US Pharma segment EBIT

299 MSEK

LTM1

Cash position

279 MSEK

Q1 2023

1 Last Twelve Months, Q222-Q123, for more information about financial development Link

Orexo Social

26 May 2023

Glad to have these colleagues presenting the amorphOX® drug delivery platform at the Novel Nasal Formulation & Deli… https://t.co/bLVUITar8c

24 May 2023

Tomorrow we will join Bolagsdagen hosted by Erik Penser Bank. An IRL event with more than 300 participants + 60 pre… https://t.co/l2M5u5w8CO

22 May 2023

Our partner @gesynta Pharma is developing a novel treatment for #endometriosis (phase II). Today they announces the… https://t.co/Ue74yAbNJ1